Document is current
Any future updates will be listed below
-
Authors
Mandal, Purba
Trushina, Eugenia https://orcid.org/0000-0002-6291-2860
Arnold, Matthias https://orcid.org/0000-0002-4666-0923
Kaddurah-Daouk, Rima https://orcid.org/0000-0003-1858-5732
Baloni, Priyanka https://orcid.org/0000-0002-3382-4941
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (4RF1AG055549-03)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (4RF1AG055549-03)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U01AG061359, U19AG063744, R01AG069901, U19AG074879, U01AG088562, R01AG081322)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U19AG063744, U01AG061359, R01AG081322)
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 2 June 2026
First Online: 10 June 2026
Competing interests
: E.T. is a co-inventor of four U.S. Patents, 11,161,814; 10,336,700; 10,774,045; and 12,017,992, which are relevant to the development of mitochondria-targeted therapeutics. She and the Mayo Clinic own the IP on this technology. R.K.D. is an inventor on a series of patents on the use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia, and Metabosensor. M.A. is a co-inventor (through Duke University/Helmholtz Zentrum München) on patents on applications of metabolomics in diseases of the central nervous system; M.A. holds equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in depression. The remaining authors declare that they have no competing interests.
